Clinical Trial Update: Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial protocol investigating Herceptin (trastuzumab) as adjuvant therapy with reduced chemotherapy exposure for HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Institut de cancérologie Strasbourg Europe | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING